Second Alzheimer s drug in pipeline can slow the disease by a few months but with safety risk columbian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from columbian.com Daily Mail and Mail on Sunday newspapers.
WASHINGTON Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease after the recently…
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study.
If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease after rival Leqembi. Both drugs pose a serious safety concern brain swelling and bleeding. Lilly's data was presented at an Alzheimer's Association international meeting Monday and published in the Journal of the American Medical Association.
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease after the recently approved…
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.